Favorable effect of sodium–glucose cotransporter 2 inhibitor, dapagliflozin, on non‐alcoholic fatty liver disease compared with pioglitazone

AIMS/INTRODUCTION: Sodium–glucose cotransporter 2 inhibitors, as well as thiazolidines, suppress nonalcoholic fatty liver disease (NAFLD); however, few comparative studies have been reported. Dapagliflozin has shown non‐inferiority compared with pioglitazone for glycemic control, and superiority reg...

Descripción completa

Detalles Bibliográficos
Autores principales: Cho, Kyu Yong, Nakamura, Akinobu, Omori, Kazuno, Takase, Takahiro, Miya, Aika, Yamamoto, Kohei, Nomoto, Hiroshi, Kameda, Hiraku, Taneda, Shinji, Kurihara, Yoshio, Aoki, Shin, Atsumi, Tatsuya, Miyoshi, Hideaki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8264405/
https://www.ncbi.nlm.nih.gov/pubmed/33131199
http://dx.doi.org/10.1111/jdi.13457

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8264405/
https://www.ncbi.nlm.nih.gov/pubmed/33131199
http://dx.doi.org/10.1111/jdi.13457

Ejemplares similares